BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 12209350)

  • 1. Mycophenolate mofetil for the treatment of acute and chronic GVHD is effective and well tolerated but induces a high risk of infectious complications: a series of 21 BM or PBSC transplant patients.
    Baudard M; Vincent A; Moreau P; Kergueris MF; Harousseau JL; Milpied N
    Bone Marrow Transplant; 2002 Sep; 30(5):287-95. PubMed ID: 12209350
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Different efficacy of mycophenolate mofetil as salvage treatment for acute and chronic GVHD after allogeneic stem cell transplant.
    Kim JG; Sohn SK; Kim DH; Lee NY; Suh JS; Lee KS; Lee KB
    Eur J Haematol; 2004 Jul; 73(1):56-61. PubMed ID: 15182339
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mycophenolate mofetil (MMF) as therapy for refractory chronic GVHD (cGVHD) in children receiving bone marrow transplantation.
    Busca A; Saroglia EM; Lanino E; Manfredini L; Uderzo C; Nicolini B; Messina C; Rabusin M; Miniero R
    Bone Marrow Transplant; 2000 May; 25(10):1067-71. PubMed ID: 10828867
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduced-intensity conditioning allogeneic transplantation from unrelated donors: evaluation of mycophenolate mofetil plus cyclosporin A as graft-versus-host disease prophylaxis.
    Pérez-Simón JA; Martino R; Caballero D; Valcarcel D; Rebollo N; de la Cámara R; de Oteiza JP; Heras I; Calvo MV; Sierra J; San Miguel JF;
    Biol Blood Marrow Transplant; 2008 Jun; 14(6):664-71. PubMed ID: 18489992
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A pilot study of tacrolimus and mycophenolate mofetil graft-versus-host disease prophylaxis in childhood and adolescent allogeneic stem cell transplant recipients.
    Osunkwo I; Bessmertny O; Harrison L; Cheung YK; Van de Ven C; del Toro G; Garvin J; George D; Bradley MB; Wolownik K; Wischhover C; Levy J; Skerrett D; Cairo MS
    Biol Blood Marrow Transplant; 2004 Apr; 10(4):246-58. PubMed ID: 15077223
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Study on graft-versus-host disease in the allogeneic peripheral blood stem cell transplantation for the treatment of leukemia].
    Zhang WP; Wang JM; Ju XP; Song XM; Tong SP; Li HM
    Zhonghua Xue Ye Xue Za Zhi; 2003 Mar; 24(3):129-33. PubMed ID: 12697123
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mycophenolate mofetil for the treatment of acute and chronic steroid-refractory graft-versus-host disease.
    Krejci M; Doubek M; Buchler T; Brychtova Y; Vorlicek J; Mayer J
    Ann Hematol; 2005 Oct; 84(10):681-5. PubMed ID: 16001244
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Prophylaxis of acute graft-versus-host disease after allogeneic bone marrow transplantation by mycophenolate mofetil in a murine model].
    Huang H; Zheng W; Lin M; Fu J; Zhang R
    Zhonghua Xue Ye Xue Za Zhi; 2002 Apr; 23(4):191-3. PubMed ID: 12133455
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Quadruple therapy with CsA, MTX, MMF and ATG for preventing graft-versus-host disease in unrelated donor hematopoietic stem cell transplantation].
    Liu QF; Sun J; Zhang Y; Xu D; Liu XL; Xu B; Meng FY; Zhou SY
    Di Yi Jun Yi Da Xue Xue Bao; 2003 Nov; 23(11):1143-5. PubMed ID: 14625172
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mycophenolate pharmacokinetics and association with response to acute graft-versus-host disease treatment from the Blood and Marrow Transplant Clinical Trials Network.
    Jacobson PA; Huang J; Wu J; Kim M; Logan B; Alousi A; Grimley M; Bolaños-Meade J; Ho V; Levine JE; Weisdorf D
    Biol Blood Marrow Transplant; 2010 Mar; 16(3):421-9. PubMed ID: 19925875
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cyclosporine A and mycophenolate mofetil vs cyclosporine A and methotrexate for graft-versus-host disease prophylaxis after stem cell transplantation from HLA-identical siblings.
    Neumann F; Graef T; Tapprich C; Vaupel M; Steidl U; Germing U; Fenk R; Hinke A; Haas R; Kobbe G
    Bone Marrow Transplant; 2005 Jun; 35(11):1089-93. PubMed ID: 15821769
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased risk of complicated CMV infection with the use of mycophenolate mofetil in allogeneic stem cell transplantation.
    Hambach L; Stadler M; Dammann E; Ganser A; Hertenstein B
    Bone Marrow Transplant; 2002 Jun; 29(11):903-6. PubMed ID: 12080355
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mycophenolate mofetil for the treatment of acute and chronic GVHD in bone marrow transplant patients.
    Basara N; Blau WI; Römer E; Rudolphi M; Bischoff M; Kirsten D; Sanchez H; Günzelmann S; Fauser AA
    Bone Marrow Transplant; 1998 Jul; 22(1):61-5. PubMed ID: 9678797
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intensified Mycophenolate Mofetil Dosing and Higher Mycophenolic Acid Trough Levels Reduce Severe Acute Graft-versus-Host Disease after Double-Unit Cord Blood Transplantation.
    Harnicar S; Ponce DM; Hilden P; Zheng J; Devlin SM; Lubin M; Pozotrigo M; Mathew S; Adel N; Kernan NA; O'Reilly R; Prockop S; Scaradavou A; Hanash A; Jenq R; van den Brink M; Giralt S; Perales MA; Young JW; Barker JN
    Biol Blood Marrow Transplant; 2015 May; 21(5):920-5. PubMed ID: 25687796
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mycophenolate mofetil is effective and well tolerated in the treatment of refractory acute and chronic graft-versus-host disease.
    Takami A; Mochizuki K; Okumura H; Ito S; Suga Y; Yamazaki H; Yamazaki M; Kondo Y; Asakura H; Nakao S
    Int J Hematol; 2006 Jan; 83(1):80-5. PubMed ID: 16443558
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extended mycophenolate mofetil and shortened cyclosporine failed to reduce graft-versus-host disease after unrelated hematopoietic cell transplantation with nonmyeloablative conditioning.
    Baron F; Sandmaier BM; Storer BE; Maris MB; Langston AA; Lange T; Petersdorf E; Bethge W; Maziarz RT; McSweeney PA; Pulsipher MA; Wade JC; Chauncey TR; Shizuru JA; Sorror ML; Woolfrey AE; Maloney DG; Storb R
    Biol Blood Marrow Transplant; 2007 Sep; 13(9):1041-8. PubMed ID: 17697966
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Prophylaxis and treatment of chronic graft versus host disease].
    Huang K; Li Y; Huang SL; Fang JP; Zhou DH; Chen C
    Zhonghua Er Ke Za Zhi; 2005 Mar; 43(3):174-7. PubMed ID: 15833186
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A prospective randomized trial comparing cyclosporine and short course methotrexate with cyclosporine and mycophenolate mofetil for GVHD prophylaxis in myeloablative allogeneic bone marrow transplantation.
    Bolwell B; Sobecks R; Pohlman B; Andresen S; Rybicki L; Kuczkowski E; Kalaycio M
    Bone Marrow Transplant; 2004 Oct; 34(7):621-5. PubMed ID: 15300236
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral beclomethasone dipropionate for the treatment of gastrointestinal chronic graft-versus-host disease.
    Villanueva FN; Pérez-Simón JA; Silva FF; Caballero-Velázquez TT; Sánchez-Guijo FF; Cañizo CC; Vázquez LL; Caballero DD; San Miguel JF
    Biol Blood Marrow Transplant; 2009 Oct; 15(10):1331-6. PubMed ID: 19747642
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A high risk of life-threatening infectious complications in mycophenolate mofetil treatment for acute or chronic graft-versus-host disease.
    Onishi C; Ohashi K; Sawada T; Nakano M; Kobayashi T; Yamashita T; Akiyama H; Sakamaki H
    Int J Hematol; 2010 Apr; 91(3):464-70. PubMed ID: 20217287
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.